<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169492</url>
  </required_header>
  <id_info>
    <org_study_id>NV-PMK-1203</org_study_id>
    <nct_id>NCT02169492</nct_id>
  </id_info>
  <brief_title>Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke</brief_title>
  <acronym>Re-ACT</acronym>
  <official_title>Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke: An Observational, Prospective and Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codman &amp; Shurtleff</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codman &amp; Shurtleff</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the ReVive SE
      (Self- Expanding) Neurothrombectomy Device in subjects requiring mechanical thrombectomy when
      used according to its Instruction for use (IFU).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>90 days</time_frame>
    <description>Functional Independence of subjects as defined by modified Rankin Scale (mRS) ≤2 at 90 days post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>emboli occurence</measure>
    <time_frame>90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">103</enrollment>
  <condition>Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        subjects requiring mechanical thrombectomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Clinical signs consistent with acute ischemic stroke

          3. No pre-stroke functional dependence (pre-stroke Modified Rankin Score ≤ 1)

          4. NIHSS ≥ 6,, assessed within two hours before treatment with ReVive SE

          5. Large (≥ 1.5mm) and proximal vessel occlusion (presenting TICI score of 0 or 1) of MCA
             (M1-M2), dICA, or BA confirmed by CT/MR angiography that it is accessible to the
             ReVive SE.

          6. Treatment initiated within 8 hours after symptom onset (first ReVive SE pass made
             within 6 hours

          7. Subject or legally authorized representative has provided informed consent on data
             collection, and consent is documented

        Exclusion Criteria:

          1. Life expectancy of less than 90 days

          2. Neurological signs that are rapidly improving prior to or at time of treatment (NIHSS
             improves at least 4 points between subject presentation and treatment initiation)

          3. Subject is either exhibiting clinical signs suggestive of, or there is angiographic
             evidence of bilateral stroke

          4. Prior use of any other mechanical device to treat this stroke (e.g., Merci Retriever,
             Penumbra, Solitaire, Trevo, Mindframe, Phenox, stent)

          5. Known bleeding diathesis:

               1. Current use of oral anticoagulants (eg, warfarin sodium) with International
                  Normalized Ratio (INR) &gt; 3;

               2. Administration of heparin or Novel Oral AntiCoagulants (NOAC, eg Dabigatran,
                  Rivaroxaban) within 48 hours preceding the onset of stroke and have an abnormal
                  activated partial thromboplastin time (aPTT) at presentation; and/or

               3. Platelet count &lt; 100,000/mm3

          6. Glucose &lt;50 mg/dL (2.8 mmol, 2.6mM)

          7. Uncontrolled hypertension (SBP&gt;185 or DBP&gt;110) refractory to pharmacological
             management

          8. Known hypersensitivity or allergy to nitinol and/or radiographic contrast agents

          9. Pregnancy or lactating female

         10. Subject already enrolled in a clinical study involving experimental medication or
             device

             Imaging Exclusion criteria:

         11. CT scan or MRI with evidence of acute intracranial hemorrhage, mass effect and/or
             intracranial tumor.

         12. Angiographic evidence of carotid dissection, or high grade stenosis (&gt; 50% stenosis of
             the artery proximal to the target vessel) that will prevent access to the clot, or
             cerebral vasculitis

         13. Blood vessel with extreme tortuosity or other conditions preventing the access of the
             device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Hoehn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Codman Neuro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne</name>
      <address>
        <city>St Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombectomy</keyword>
  <keyword>Stroke</keyword>
  <keyword>ReVive SE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

